Impact of patient factors on recurrence risk and time dependency of oxaliplatin benefit in patients with colon cancer: Analysis from modern-era adjuvant studies in the adjuvant colon cancer end points (ACCENT) database

Manish A. Shah, Lindsay A. Renfro, Carmen J. Allegra, Thierry André, Aimery De Gramont, Hans Joachim Schmoll, Daniel G. Haller, Steven Robert Alberts, Greg Yothers, Daniel J. Sargent

Research output: Contribution to journalArticle

37 Citations (Scopus)

Abstract

Purpose: Fluorouracil plus leucovorin (FU + LV) adjuvant chemotherapy reduced the risk of recurrence and death across all time points in a pooled analysis of 20,898 patients with colon cancer from 18 randomized studies. The impact of oxaliplatin added to FU + LV on the time course of recurrence and survival remains unknown. Patients and Methods: A total of 12,233 patients enrolled to the randomized trials C-07, C-08, N0147, MOSAIC (Adjuvant Treatment of Colon Cancer), and XELOXA (Adjuvant XELOX) were pooled to examine the impact of oxaliplatin and tumor-specific factors on the time course of recurrence and death. For each end point, continuous-time risk was modeled over 6 years post treatment in all oxaliplatin-treated patients and patients concurrently randomized to FU + LV with or without oxaliplatin; the latter analyses supported time-dependent treatment comparisons. Results: Addition of oxaliplatin significantly reduced the risk of recurrence within the first 14 months post treatment for patients with stage II disease and within the first 4 years for patients with stage III disease. Oxaliplatin also significantly reduced risk of death from 2 to 6 years post treatment for patients with stage III disease, with no differences in timing of outcomes between treatment groups (ie, oxaliplatin did not simply postpone recurrence or death compared with FU + LV alone). Patients with stage II disease receiving oxaliplatin did not exhibit a significant reduction in risk of death in the first 6 years post treatment. Recurrence risk peaked near 14 months for both treatments, and risk of recurrence and death increased with increased tumor and nodal burden. Conclusions: These analyses support the addition of oxaliplatin to fluoropyrimidine-based adjuvant therapy in patients with stage III disease and underscore the need for adequate surveillance of patients with colon cancer during the first 3 years after adjuvant therapy.

Original languageEnglish (US)
Pages (from-to)843-853
Number of pages11
JournalJournal of Clinical Oncology
Volume34
Issue number8
DOIs
StatePublished - Mar 10 2016

Fingerprint

oxaliplatin
Colonic Neoplasms
Databases
Recurrence
Therapeutics

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Impact of patient factors on recurrence risk and time dependency of oxaliplatin benefit in patients with colon cancer : Analysis from modern-era adjuvant studies in the adjuvant colon cancer end points (ACCENT) database. / Shah, Manish A.; Renfro, Lindsay A.; Allegra, Carmen J.; André, Thierry; De Gramont, Aimery; Schmoll, Hans Joachim; Haller, Daniel G.; Alberts, Steven Robert; Yothers, Greg; Sargent, Daniel J.

In: Journal of Clinical Oncology, Vol. 34, No. 8, 10.03.2016, p. 843-853.

Research output: Contribution to journalArticle

Shah, Manish A. ; Renfro, Lindsay A. ; Allegra, Carmen J. ; André, Thierry ; De Gramont, Aimery ; Schmoll, Hans Joachim ; Haller, Daniel G. ; Alberts, Steven Robert ; Yothers, Greg ; Sargent, Daniel J. / Impact of patient factors on recurrence risk and time dependency of oxaliplatin benefit in patients with colon cancer : Analysis from modern-era adjuvant studies in the adjuvant colon cancer end points (ACCENT) database. In: Journal of Clinical Oncology. 2016 ; Vol. 34, No. 8. pp. 843-853.
@article{2388a3c78da548b297e1b3988f9d33cd,
title = "Impact of patient factors on recurrence risk and time dependency of oxaliplatin benefit in patients with colon cancer: Analysis from modern-era adjuvant studies in the adjuvant colon cancer end points (ACCENT) database",
abstract = "Purpose: Fluorouracil plus leucovorin (FU + LV) adjuvant chemotherapy reduced the risk of recurrence and death across all time points in a pooled analysis of 20,898 patients with colon cancer from 18 randomized studies. The impact of oxaliplatin added to FU + LV on the time course of recurrence and survival remains unknown. Patients and Methods: A total of 12,233 patients enrolled to the randomized trials C-07, C-08, N0147, MOSAIC (Adjuvant Treatment of Colon Cancer), and XELOXA (Adjuvant XELOX) were pooled to examine the impact of oxaliplatin and tumor-specific factors on the time course of recurrence and death. For each end point, continuous-time risk was modeled over 6 years post treatment in all oxaliplatin-treated patients and patients concurrently randomized to FU + LV with or without oxaliplatin; the latter analyses supported time-dependent treatment comparisons. Results: Addition of oxaliplatin significantly reduced the risk of recurrence within the first 14 months post treatment for patients with stage II disease and within the first 4 years for patients with stage III disease. Oxaliplatin also significantly reduced risk of death from 2 to 6 years post treatment for patients with stage III disease, with no differences in timing of outcomes between treatment groups (ie, oxaliplatin did not simply postpone recurrence or death compared with FU + LV alone). Patients with stage II disease receiving oxaliplatin did not exhibit a significant reduction in risk of death in the first 6 years post treatment. Recurrence risk peaked near 14 months for both treatments, and risk of recurrence and death increased with increased tumor and nodal burden. Conclusions: These analyses support the addition of oxaliplatin to fluoropyrimidine-based adjuvant therapy in patients with stage III disease and underscore the need for adequate surveillance of patients with colon cancer during the first 3 years after adjuvant therapy.",
author = "Shah, {Manish A.} and Renfro, {Lindsay A.} and Allegra, {Carmen J.} and Thierry Andr{\'e} and {De Gramont}, Aimery and Schmoll, {Hans Joachim} and Haller, {Daniel G.} and Alberts, {Steven Robert} and Greg Yothers and Sargent, {Daniel J.}",
year = "2016",
month = "3",
day = "10",
doi = "10.1200/JCO.2015.63.0558",
language = "English (US)",
volume = "34",
pages = "843--853",
journal = "Journal of Clinical Oncology",
issn = "0732-183X",
publisher = "American Society of Clinical Oncology",
number = "8",

}

TY - JOUR

T1 - Impact of patient factors on recurrence risk and time dependency of oxaliplatin benefit in patients with colon cancer

T2 - Analysis from modern-era adjuvant studies in the adjuvant colon cancer end points (ACCENT) database

AU - Shah, Manish A.

AU - Renfro, Lindsay A.

AU - Allegra, Carmen J.

AU - André, Thierry

AU - De Gramont, Aimery

AU - Schmoll, Hans Joachim

AU - Haller, Daniel G.

AU - Alberts, Steven Robert

AU - Yothers, Greg

AU - Sargent, Daniel J.

PY - 2016/3/10

Y1 - 2016/3/10

N2 - Purpose: Fluorouracil plus leucovorin (FU + LV) adjuvant chemotherapy reduced the risk of recurrence and death across all time points in a pooled analysis of 20,898 patients with colon cancer from 18 randomized studies. The impact of oxaliplatin added to FU + LV on the time course of recurrence and survival remains unknown. Patients and Methods: A total of 12,233 patients enrolled to the randomized trials C-07, C-08, N0147, MOSAIC (Adjuvant Treatment of Colon Cancer), and XELOXA (Adjuvant XELOX) were pooled to examine the impact of oxaliplatin and tumor-specific factors on the time course of recurrence and death. For each end point, continuous-time risk was modeled over 6 years post treatment in all oxaliplatin-treated patients and patients concurrently randomized to FU + LV with or without oxaliplatin; the latter analyses supported time-dependent treatment comparisons. Results: Addition of oxaliplatin significantly reduced the risk of recurrence within the first 14 months post treatment for patients with stage II disease and within the first 4 years for patients with stage III disease. Oxaliplatin also significantly reduced risk of death from 2 to 6 years post treatment for patients with stage III disease, with no differences in timing of outcomes between treatment groups (ie, oxaliplatin did not simply postpone recurrence or death compared with FU + LV alone). Patients with stage II disease receiving oxaliplatin did not exhibit a significant reduction in risk of death in the first 6 years post treatment. Recurrence risk peaked near 14 months for both treatments, and risk of recurrence and death increased with increased tumor and nodal burden. Conclusions: These analyses support the addition of oxaliplatin to fluoropyrimidine-based adjuvant therapy in patients with stage III disease and underscore the need for adequate surveillance of patients with colon cancer during the first 3 years after adjuvant therapy.

AB - Purpose: Fluorouracil plus leucovorin (FU + LV) adjuvant chemotherapy reduced the risk of recurrence and death across all time points in a pooled analysis of 20,898 patients with colon cancer from 18 randomized studies. The impact of oxaliplatin added to FU + LV on the time course of recurrence and survival remains unknown. Patients and Methods: A total of 12,233 patients enrolled to the randomized trials C-07, C-08, N0147, MOSAIC (Adjuvant Treatment of Colon Cancer), and XELOXA (Adjuvant XELOX) were pooled to examine the impact of oxaliplatin and tumor-specific factors on the time course of recurrence and death. For each end point, continuous-time risk was modeled over 6 years post treatment in all oxaliplatin-treated patients and patients concurrently randomized to FU + LV with or without oxaliplatin; the latter analyses supported time-dependent treatment comparisons. Results: Addition of oxaliplatin significantly reduced the risk of recurrence within the first 14 months post treatment for patients with stage II disease and within the first 4 years for patients with stage III disease. Oxaliplatin also significantly reduced risk of death from 2 to 6 years post treatment for patients with stage III disease, with no differences in timing of outcomes between treatment groups (ie, oxaliplatin did not simply postpone recurrence or death compared with FU + LV alone). Patients with stage II disease receiving oxaliplatin did not exhibit a significant reduction in risk of death in the first 6 years post treatment. Recurrence risk peaked near 14 months for both treatments, and risk of recurrence and death increased with increased tumor and nodal burden. Conclusions: These analyses support the addition of oxaliplatin to fluoropyrimidine-based adjuvant therapy in patients with stage III disease and underscore the need for adequate surveillance of patients with colon cancer during the first 3 years after adjuvant therapy.

UR - http://www.scopus.com/inward/record.url?scp=84962512686&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84962512686&partnerID=8YFLogxK

U2 - 10.1200/JCO.2015.63.0558

DO - 10.1200/JCO.2015.63.0558

M3 - Article

C2 - 26811529

AN - SCOPUS:84962512686

VL - 34

SP - 843

EP - 853

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

SN - 0732-183X

IS - 8

ER -